DaVita Clinical Research and Pyxant Labs to Collaborate on Clinical Trials - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
DaVita Clinical Research and Pyxant Labs to Collaborate on Clinical Trials


DaVita Clinical Research and Pyxant Labs to Collaborate on Clinical Trials

PR Newswire

MINNEAPOLIS, Feb. 12, 2014 /PRNewswire-USNewswire/ -- DaVita Clinical Research ® (DCR®), a specialty contract research organization with services spanning the full spectrum of drug and device development, announced today that it has entered into an agreement through which Pyxant Labs Inc. will provide bioanalytical laboratory services for DCR's early clinical trials.

(Logo: http://photos.prnewswire.com/prnh/20140212/DC63568LOGO)

"Pyxant's proven track record and overall commitment to high quality aligns well with our strategic growth objectives for early clinical research," said Chad Jaeger, vice president of early clinical research at DCR. "This collaboration represents another step forward in providing comprehensive services aimed at accelerating drug development."

Pyxant Labs is a contract research laboratory specializing in GLP bioanalytical chemistry support for life sciences clients. As part of the relationship, Pyxant will provide bioanalytical method development, sample analysis and formulation development for early clinical trials conducted at DCR's clinical research units.

"We are excited to further extend our collaboration with the great team at DCR. DCR has built the best clinical research site that I have toured in the last 10 years. Their operations team at the site, corporate culture and high ethical approach made a compelling case for our association," said Maurice Gaubatz, president and CEO of Pyxant Labs. "Pairing DCR's clinical execution with Pyxant's bioanalytical services is a winning combination, exactly in line with our respective core competencies." 

To learn more about DCR and upcoming clinical research trials, visit participateDaVita.com or DCR on Facebook.

DaVita HealthCare Partners, DaVita Clinical Research, and DCR are trademarks or registered trademarks of DaVita HealthCare Partners Inc. Pyxant and Pyxant Labs are trademarks or registered trademarks of Pyxant Labs Inc. All other trademarks are the property of their respective owners.

About DaVita Clinical Research
DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita HealthCare Partners Inc. (NYSE: DVA), uses its extensive, applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment and completion of retrospective, prospective pragmatic and clinical trials. DCR's scientific and clinical expertise spans the lifecycle of product development with more than 150 client companies. DCR's Biorepository , Early Clinical Research unit (Phase I-IIa) and Clinical Development (Phase IIb through post-marketing) network of physicians and investigative sites, data research, Health Economics & Outcomes Research , and Medical Communications are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit www.davitaclinicalresearch.com .

About Pyxant Labs
Pyxant Labs is a leading bioanalytical CRO, supporting clinical and non-clinical drug development programs for pharmaceutical companies. Pyxant develops bioanalytical assays, validates methods, and assays samples, all in compliance with FDA regulatory requirements.Pyxant provides bioanalytical for GLP animal studies through Phase III clinical development. Our scientific and regulatory leadership, FDA compliance record, and stable team of scientists have allowed us to grow at better than 20% per year, from long standing ongoing relationships with four dozen clients. For more about Pyxant Labs, visit www.pyxant.com.

Media Contact:
Bianca Violante
Office: (303) 876-6614
Mobile: (443) 417-6044
Bianca.Violante@DaVita.com

SOURCE DaVita Clinical Research

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
88%
Borrow lightly from EMA's pathway program?
4%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here